Article Figures & Data
Figures
- FIGURE 1.
Radioactive retention of 99mTc-radiopharmaceuticals, prepared from kits according manufacturer instructions for different brands of syringes after 30 min of incubation time: brand A (A); brand B (B). DPD = butedronate; HDP = oxidronate; MDP = medronate; MIBI = sestamibi.
- FIGURE 2.
Radioactive retention: 99mTc-sestamibi in brand B syringes as function of sestamibi concentration.
- FIGURE 3.
Radioactive retention of 99mTc-succimer, radiochemically prepared without inositol in different brands of syringes after 30 min of incubation time.
- FIGURE 4.
Radioactive retention: 99mTc-succimer in brand B syringes as function of concentration of excipient inositol.
Tables
Radiopharmaceutical Kit Ingredients Reconstitution 99mTc-butedronate Teceos (CIS Bio) 13 mg of 3,3 diphospho-1,2-propanedicarboxylic acid, tetrasodium salt (butedronate), SnCl2⋅2H2O, N-(4-aminobenzoyl)-l-glutamic acid 99mTc-TcO4− 2–10 mL, 0.4–11.1 GBq (10–300 mCi), 5 min of shaking, room temperature Butedronate 1.3–6.5 mg/mL 99mTc-oxidronate Technescan oxidronate (Mallinckrodt) 3 mg of disodium-oxidronate, SnCl2⋅2H2O, gentisinic acid, sodium chloride 99mTc-TcO4− 3–10 mL, 1.5–11.1 GBq (40–300 mCi), 0.5 min of shaking, room temperature Oxidronate 0.3–1.0 mg/mL 99mTc-medronate Medronate Tc-IK-10 (Izotop) 5 mg of medronic acid (medronate), SnCl2⋅2H2O, ascorbic acid, urea 99mTc-TcO4− 2–5 mL, 3–6 GBq (80–160 mCi), 15 min of incubation, room temperature Medronate 1–2.5 mg/mL 99mTc-tetrofosmin Myoview (GE Healthcare) 0.23 mg of tetrofosmin, SnCl2⋅2H2O, disodium sulphosalicylate, sodium d-gluconate, sodium hydrogen carbonate 99mTc-TcO4− 4–8 mL, <8.8 GBq (<240 mCi), 15 min of incubation, room temperature Tetrofosmin 0.03–0.06 mg/mL 99mTc-sestamibi Stamicis (CIS Bio) 1 mg of tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, SnCl2⋅2H2O, cysteine hydrochloride monohydrate, sodium citrate, mannitol 99mTc-TcO4− 1–3 mL, 0.2–11 GBq (5–290 mCi), 10 min of incubation, 100°C Sestamibi 0.33–1 mg/mL 99mTc-DMSA (99mTc-succimer) Renocis (CIS Bio) 1 mg of dimercaptosuccinic acid, SnCl2⋅2H2O, ascorbic acid, inositol 99mTc-TcO4− 1–6 mL, <3.7 GBq (<100 mCi), 5–10 min of shaking, room temperature DMSA 0.17–1 mg/mL - TABLE 2
Radioactive Retention of 99mTc-Radiopharmaceuticals in Syringes and Needles after 30 Minutes of Incubation
Retention in syringe (%) Radiopharmaceutical Syringe brand Undiluted 1:3 with saline 1:10 with saline Retention in needle (%) (undiluted) 99mTc-pertechnetate A 1.3 ± 1.0 1.5 ± 0.8 4.8 ± 1.1 4.5 ± 1.1 B 1.9 ± 0.3 1.1 ± 0.1 1.4 ± 1.0 2.9 ± 1.6 99mTc-butedronate A 3.6 ± 0.6 2.1 ± 0.5 1.6 ± 0.8 4.3 ± 0.2 B 2.6 ± 0.8 2.2 ± 0.3 2.1 ± 0.7 2.0 ± 0.4 99mTc-oxidronate A 2.1 ± 1.8 2.8 ± 1.7 1.6 ± 0.8 2.9 ± 1.9 B 1.8 ± 1.8 2.2 ± 0.2 2.3 ± 0.5 3.0 ± 1.3 99mTc-medronate A 2.4 ± 0.3 1.4 ± 1.2 2.1 ± 2.3 3.9 ± 0.4 B 1.7 ± 1.1 1.1 ± 0.6 1.8 ± 0.7 2.4 ± 0.5 99mTc-tetrofosmin A 6.7 ± 0.8 5.9 ± 1.8 4.7 ± 1.8 6.7 ± 1.0 B 6.0 ± 0.3 3.5 ± 0.8 3.8 ± 0.7 3.1 ± 0.4 99mTc-sestamibi A 6.9 ± 3.6 7.3 ± 1.6 13.0 ± 2.5 5.2 ± 0.2 B 3.3 ± 1.1 6.3 ± 0.8 9.0 ± 0.9 2.5 ± 0.2 99mTc-succimer A 10.7 ± 1.4 9.8 ± 1.9 6.9 ± 0.2 13.9 ± 0.2 B 13.9 ± 2.0 14.2 ± 1.1 19.5 ± 4.3 6.9 ± 0.2 99mTc-DMSA(V) pentavalent A 1.8 ± 0.3 2.2 ± 0.2 2.1 ± 1.2 4.5 ± 0.9 B 2.4 ± 0.3 2.4 ± 0.6 2.0 ± 0.5 1.7 ± 0.5
